lindas have a posse
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Landmark Trial Results!
JAMA!
MHRA Trial Endorsement (PIP)!
MHRA-endorsed Manufacturing (MIA)!
Global Patent Protection!
Mechanism of Action for All Solid Tumors!
My 560K shares should be worth $45M or more once Northwest Biotherapeutics obtains global approval on nGBM and rGBM indications.
I see no reason to sell my shares since I can borrow against them once NWBO are off OTC.
In my personal opinion as a retail investor representing myself alone, and not providing investment advice, longs must focus upon the deep value present in Northwest Biotherapeutics stock!
Billionaire Robert Hefner agrees:
Our Northwest Biotherapeutics (NWBO) investee “partner” likely has just made one of the biggest breakthroughs in the history of cancer. We know that is a really big statement so why do we at GHK believe that is possible? Because we believe the doors through which major cancer breakthroughs must pass are the human immune system, immunotherapies and personalized vaccines and NWBO has just leaped through those doors with its personalized DCVax vaccine made from your own cells.
You can argue about trial statistics until the cows come home but the bottom line is 1) people living longer 2) quality of life during treatments and 3) the cost of treatments.
During NWBO’s 16-year Phase III trial to treat glioblastoma (GBM), one of the most difficult and lethal of all solid tumor cancers 1) more people lived longer, 2) it is safe with virtually no side effects occurring and 3) NWBO estimates treatments will cost about half as much as Standard of Care chemotherapy and radiation treatments. So for the first time ever, GBM patients can have hope! And can hope like prayer increase the effectiveness and energy of the immune system? We think so.
We are aware we stuck our necks out when we said “possibly one of the biggest breakthroughs in the history of cancer”. So we have listed below our three principle reasons so you can decide for yourself:
After 417 failed GBM trials treating 31,952 patents over decades, DCVax-L is first treatment that gives GBM patients a meaningful chance to live longer, some now living 9 to as many as 19 years and counting.
DCVax was conceived and created not for glioblastoma alone but as a personalized tool of your own immune system to defeat all solid tumor cancers and that’s 90% of all cancers.
Since DCVax’s creation NWBO has amassed an enormous rich databank containing masses of information on patients, treatments, and DCVax’s use against 15 different solid tumor cancers that has not yet been analyzed by artificial intelligence (AI). We believe that in the near future when these vast amounts of data and information are teamed with AI and some of the world’s leading scientists and doctors that future generations of DCVax vaccines and protocols will experience great leaps forward in effectiveness at lower and lower costs for 90% of all cancers.
So to sum up, we believe NWBO with its DCVax immunotherapy personalized vaccines has leaped through the doors and will play a vital role in humanities great drive to defeat cancer once and for all.
Dr. Ashkan is the genius behind this viral vid of him performing brain surgery while his patient was awakened to play the violin…mid-surgery. He told me he champions DCVax-L bc of trial data along with what he’s seen first-hand from his patients. $NWBOhttps://t.co/XFTeSPFtH5
— Wade Kovash (@wkovash) June 6, 2022
Watch one of the world’s preeminent neurosurgeons explain the significance of $NWBO ‘s Phase III trial of DCVax-L. The results are groundbreaking and represent an enormous advancement in one of the most tragic cancers. https://t.co/eQw5tAsivK
— Wade Kovash (@wkovash) June 6, 2022
Trillion dollar technology. If you don't understand that's your issue not management.
The trial showed an increase in overall survival. It didn't contain subgroup analysis which only occurs when the primary endpoints fail. We met all endpoints with super statistical significance as well as hazard ratios that show the results were not random.
The idea that DCVax doesn't benefit all patients vs SOC isn't true otherwise it wouldn't be the focal point of UCLA research for GBM. Some respond better than others but by in large it works well enough for approval.
Each year in the US about 200 million flu shot doses are distributed. There isnt that kind of demand for DCVax. I don't ever see it being given in a retail pharmacy.
Flu shots are not personalized so I do not see DCVax, which requires major surgery and leukapheresis, being delivered in a retail pharmacy. I took community setting meaning a local non academic research hospital which was the example given by Dr Bosch.
In addition Sawston UK and Memphis TN are in close proximity to major freight airports. As many know Memphis is the global hub for FedEx. I don't anticipate distribution will be any challenge.
He's a great guy.
I smell bullshit.
If you think short sellers are correct about NWBO then that's your prerogative.
If you ask Dave about Dr Liau he will probably say that. Why don't you ask instead of expecting us to do your work? We are not your interns.
Mr Innes does not represent Dr Liau.
Your citation is bullshit.
Exercising warrants for shares creates a taxable event based upon strike price (price paid to company for each share) and the prevailing share price.
The discrepancy between the price of the stock warrant and the stock’s standard market value that the holder gets on exercising the stock warrant is taxable income.
Outstanding share count isn't increasing comparatively that much whereas that number does not signify that warrant holders are selling shares after exercising those derivatives. Certainly there's no mad rush to dump common as our low volume indicates!
In reality it makes no sense for warrant holders to sell if the price will appreciate significantly though it does behoove them, from tax standpoint, to convert warrants to shares now before a large increase in the share price occurs.
Combined with insiders engaging in estate planning in fact I see the increase in outstanding shares as a positive indicator of impending news. Any astute investor knows these warrants were going to be converted as that's the purpose of a derivative.
I agree Dan. In the eyes of the SEC any company in discussions with regulators on drug approval must be accurate in their representations of what regulators communicate especially with regards to negative feedback.
We have not received any from the company so I believe we are in a good position. The issued MIA and approved PIP provide context as do the accepted amended Statistical Analysis Plan. There's been many opportunities for regulators to say "no" while it would be unambiguous fraud for management to withhold any negative feedback such as CRL requiring new trial. I don't think the coauthor of NAFA and EU Patent Law, a person on impeccable character, would engage in such criminal behavior as that only harms herself financially as a large shareholder.
I personally still believe we are engaged in rolling review, as management want this across the finish line as soon as possible, so it would not be wise for the company to begin speaking publicly until that process has concluded especially given the ongoing manipulation.
Crucially would insiders engage in estate planning for this tax year if they thought approval wasn't happening in 2023? No, in my opinion, they would wait until the price falls further then do it later in the future.
I didn't see the qualifier of April 20th.
I am not fabricating anything. I spoke to Dave on May 27th. I haven't spoken with him since as I am sure he's busy dealing with the manic split personalities always blowing up his phone.
Recently no conversation. I am sure he's busy speaking to the other insecure shareholders who need daily psychological reinforcement.
I spoke with him at the end of May. He said they're working very hard to complete the regulatory filings. I didn't ask for details as that would be RegFD violation.
No, he isn't responding to me.
Yes, Rindopepimut looked great in Phase II then it failed in Phase III.
DCVax will own the GBM market with first mover advantage backed by the best approach to attack heterogeneous tumors.
We can buy them out.
Here you go again about the CMO. Guess who else has a CMO? Novocure.
The position isn't meaningful in any way. We have a scientific advisory board as well as top oncologists and patient advocacy groups behind DCVax.
Which process targets all proteins expressed on a tumor? DCVax.
End of story.
Once we have approval things will change permanently. I am quite happy with my 560K shares. Small retrace at the opening isn't concerning.
Great job Dan. I wish I had the capital for a 7 figure position.
The objective third party that vets the MOA will be the regulator. No doubt the proteomic analysis are included in regulatory applications.
Why else would they pay a firm to do this work now, when they don't have a lot of cash, unless it was necessary for approval which we know are their primary goal not publishing another journal?
Yet instead of thinking about context all you can do are raising moot points about a peer reviewed journal.
Some like attention.
Others get work done.
You don't get to dictate our excitement.
Academic rivalry only increases exposure for our JAMA paper and novel vaccine.
Northwest didn't go for PFS because they wanted to avoid waiting for OS. It was standard practice to try for PFS in clinical trials before the discovery of pseudoprogression.
He's made many negative comments on Twitter against Northwest Biotherapeutics.
A lot of lies.
Yes he's a criminal.
In the words of my retired brother in law "I don't care!"
It's called the buy, borrow, die strategy. It works best with low interest rates.
There's no reason to sell an appreciating asset when one can borrow against that equity.
Dead cats do bounce.
DCVax will change everything about oncology as well as trial design.
Our 20 and 50 day moving averages are still below the 200 so we are a ways from a golden cross. Though I am happy to be wrong. 2.50 here we come!
They obviously issue PRs when the SEC rules require it but they're not promoting an unapproved drug. I guess some would like them to violate FDA rules but they're seeking approval to save lives.